Dr Fernandez-Fernandez1 is right in raising the important new data regarding anti-angiogenic strategies in hereditary haemorrhagic telangiectasia (HHT), data which were published too late for inclusion in our review.2 Although the gene mutations inform us that HHT is a disorder caused by aberrant signalling by the transforming growth factor (TGF)-β superfamily, the context in which the gene mutations are deleterious, when functioning apparently perfectly well for the vast majority of vessels, has always proved tantalising. In 2009, there has been a resurgent interest in the role of angiogenesis in provoking or unmasking an HHT phenotype, with animal models particularly implicating a role for aberrant angiogenesis during wound healing.3 Pathogenesis-based treatment strategies based on case reports using anti-VEGF (bevacizumab/Avastin),4, 5, 6 interferon,7, 8 and thalidomide9, 10 are being assessed in ongoing clinical trials at HHT centres. For any efficacious agent, side-effect profiles are likely to be crucial in determining whether the use of any efficacious agents can become more widespread within the HHT patient population. In 2009, encouraging data were also reported for two better-tolerated agents, N-acetyl cysteine (trial data for 600 mg tds)11 and tamoxifen (randomised placebo-control trial data for 20 mg/day).12 These have been introduced into specialised HHT practice, reflecting the rapidly advancing field.
References
Fernandez-Fernandezovani FJ : Hereditary haemorrhagic telangiectasia: from symptomatic management to pathogenesis based treatment. Eur J Hum Genet 2009, doi:10.1038/ejhg.2009.188 (this issue).
Govani FS, Shovlin CL : Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17: 860–871.
Park SO, Wankhede M, Lee YJ et al: Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 1 October 2009. pii: 39482. doi: 10.1172/JCI39482 [Epub ahead of print].
Mitchell A, Adams LA, MacQuillan G, Tibballs J, van den Driesen R, Delriviere L : Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplant 2008; 14: 210–213.
Bose P, Holter JL, Selby GB : Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143–2144.
Simonds J, Miller F, Mandel J, Davidson TM : The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988–992.
Massoud O, Youssef W, Mullen K : Resolution of hereditary hemorrhagic telangiectasia and anemia with prolonged [alpha]-interferon therapy for chronic hepatitis C. J Clin Gastroenterol 2004; 38: 377–379.
Wheatley-Price P, Shovlin C, Chao D : Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2005; 39: 344–345.
Kurstin R : Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology (Williston Park) 2002; 16: 21–24.
Pérez-Encinas M, Rabuñal Martínez MJ, Bello López JL : Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica 2002; 87: ELT34.
de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ : The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47: 85–88.
Yaniv E, Preis M, Hadar T, Shvero J, Haddad M : Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284–288.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shovlin, C., Govani, F. Reply to Fernández-Fernández. Eur J Hum Genet 18, 404–405 (2010). https://doi.org/10.1038/ejhg.2009.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejhg.2009.197